Merus N.V. (MRUS)
| Market Cap | 907.69M |
| Revenue (ttm) | 38.32M |
| Net Income (ttm) | -88.58M |
| Shares Out | 38.48M |
| EPS (ttm) | -2.65 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 513,145 |
| Open | 23.74 |
| Previous Close | 23.59 |
| Day's Range | 22.39 - 23.74 |
| 52-Week Range | 11.19 - 31.27 |
| Beta | 0.60 |
| Analysts | Buy |
| Price Target | 19.67 (-14.1%) |
| Est. Earnings Date | Nov 4, 2021 |
About MRUS
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trial for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 for the pancreatic and lung cancer, and other solid tumors. The company is also developing MCLA-117 that is in phase I clinical trial for the treatment of patients with acute myeloid leukemia; MCLA-1...
Financial Performance
In 2020, Merus N.V.'s revenue was $29.94 million, a decrease of -3.82% compared to the previous year's $31.13 million. Losses were -$85.51 million, 55.1% more than in 2019.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for Merus N.V. stock is "Buy." The 12-month stock price forecast is 19.67, which is a decrease of -14.12% from the latest price.
News
Merus N.V. (MRUS) Reports Q2 Loss, Tops Revenue Estimates
Merus N.V. (MRUS) delivered earnings and revenue surprises of -18.33% and 58.06%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Merus Announces Financial Results for the Second Quarter and Provides Business Update
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we”, or “our”), a clinical-stage oncology company developing innovati...
Earnings Preview: Merus N.V. (MRUS) Q2 Earnings Expected to Decline
Merus N.V. (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merus to Participate in William Blair's Biotech Focus Conference 2021
UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies ...
Merus Presents Clinical Data on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Clinical Onco...
- 61 patients with NRG1+ cancer have been enrolled, including 45 patients evaluable for response as of the April 13, 2021 data cutoff date- Encouraging early clinical activity observed, with confirmed...
Merus to Participate in a Fireside Chat at the Jefferies Virtual Healthcare Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (...
Merus Announces Publication of Abstract on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the American Society of Cl...
- 51 patients with NRG1+ cancer have been treated, including 33 patients evaluable for response, as of the January 12, 2021, data cutoff date- Encouraging early clinical activity observed, with conf...
Merus N.V. (MRUS) Moves 13% Higher: Will This Strength Last?
Merus N.V. (MRUS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Merus N.V. (MRUS) Reports Q1 Loss, Lags Revenue Estimates
Merus N.V. (MRUS) delivered earnings and revenue surprises of -27.27% and -63.08%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Merus Announces Financial Results for the First Quarter and Provides Business Update
Clinical data update on zenocutuzumab selected for oral presentation at ASCO MCLA-145 clinical update planned for 2H21 MCLA-129 first patient dosed in phase 1/2 trial Cecile Geuijen, Ph.D., promoted ...
Merus Announces First Patient Treated in Phase 1/2 Clinical Trial of MCLA-129 in Advanced Lung Cancer and Other Solid...
Merus' Fourth Sponsored Bispecific Antibody Currently in Clinical Trials Merus' Fourth Sponsored Bispecific Antibody Currently in Clinical Trials
Zenocutuzumab Clinical Data Selected for Oral Presentation at the 2021 American Society of Clinical Oncology Annual M...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovat...
Merus N.V. (MRUS) Reports Q4 Loss, Tops Revenue Estimates
Merus N.V. (MRUS) delivered earnings and revenue surprises of -26.23% and 11.19%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Merus Announces Financial Results for the Fourth Quarter and Full Year 2020 and Provides Business Update
Clinical data and program update planned for lead program zenocutuzumab (“Zeno”) in 2Q 2021
Merus Announces Poster Presentations for Zenocutuzumab and MCLA-129 at the American Association for Cancer Research 2...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovat...
Merus to Participate in a Fireside Chat at the 33rd Annual Roth Conference
UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 08, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies...
Merus N.V. (MRUS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
Merus N.V. (MRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merus Announces Pricing of Public Offering of Common Shares
UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we” and “our”), a clinical-stage oncology company developing innovative, full-lengt...
Merus N.V. Announces Proposed Public Offering of Common Shares
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we” and “our”), a clinical-stage oncology company developing innovative, full-length...
Why Aclaris, Tenax, Gritstone, Merus, Minerva And Celyad Are Rallying Today
A slew of biopharma stocks are making big moves Tuesday on the back of clinical trial readouts as well announcements regarding M&A and tie-ups. Merus, Lilly In $1.68B Oncology Deal: Dutch-based Merus NV...
Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies
INDIANAPOLIS and UTRECHT, The Netherlands, Jan. 19, 2021 /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: MRUS), a c...
Merus Announces Collaborations with Nationwide Medical Organizations in the Netherlands and Japan to Enhance Screenin...
UTRECHT, The Netherlands, and CAMBRIDGE, Mass., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies...
Merus Announces Presentation of Phase 1 Clinical Data for MCLA-158 at the American Society of Clinical Oncology (ASCO...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovati...
Merus (MRUS) Stock Up on FDA's Fast Track Tag for Zenocutuzumab
The FDA bestows a Fast Track status to Merus' (MRUS) lead pipeline candidate, Zenocutuzumab, for treating metastatic solid tumors harboring NRG1 gene fusions. Shares rise.
Merus Granted FDA Fast Track Designation of Zenocutuzumab for the Treatment of Patients with Neuregulin 1 Fusion Cancers
NRG1 fusions are rare mutations in many types of solid tumors, including non-small cell lung cancer and pancreatic cancer NRG1 fusions are rare mutations in many types of solid tumors, including non-sma...